Keyword Analysis & Research: cdk inhibitor

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
cdk inhibitor1.740.818226713
cdk1.570.83710503
inhibitor0.60.57355649

Keyword Research: People who searched cdk inhibitor also searched

Keyword CPC PCC Volume Score
cdk inhibitor0.960.799750

Search Results related to cdk inhibitor on Search Engine

  • CDK inhibitors in cancer therapy, an overview of recent …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167670/

    WEBMay 15, 2021 · CDK inhibitors have been studied since the 1990s. The first generation of CDK inhibitors are pan-CDK inhibitors, including Flavopiridol and Roscovitine, etc. The main function of these inhibitors is to block cell cycle and inhibit cell proliferation by inhibiting the CDK enzyme activity.

    DA: 35 PA: 37 MOZ Rank: 3

  • CDK inhibitor - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/CDK_inhibitor

    WEBA CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells . The US FDA approved the first drug of this type, palbociclib (Ibrance), [1] a CDK4 / 6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that ...

    DA: 66 PA: 94 MOZ Rank: 61

  • What Are CDK4/6 Inhibitors? - Breastcancer.org

    breastcancer.org

    https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors

    WEBCDK4/6 inhibitors are a class of medicines used to treat certain types of hormone receptor-positive, HER2-negative breast cancer. These medicines interrupt the process through which breast cancer cells divide and multiply. To do this, they target specific proteins known as the cyclin-dependent kinases 4 and 6, abbreviated as CDK4/6.

    DA: 15 PA: 91 MOZ Rank: 83

  • CDK inhibitors in cancer therapy, an overview of recent ... - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/34094661/

    WEBMay 15, 2021 · To date, the CDK inhibitors (CDKIs), specifically the ones that block the enzyme activity of CDK4 and CDK6 (CDK4/6), have been approved by FDA for the treatment of metastatic hormone receptor positive breast cancer.

    DA: 92 PA: 36 MOZ Rank: 6

  • Targeting CDK4 and CDK6 in cancer | Nature Reviews Cancer

    nature.com

    https://www.nature.com/articles/s41568-022-00456-3

    WEBMar 18, 2022 · Abstract. Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular transition into S phase and are important for the initiation, growth and survival of many cancer types....

    DA: 83 PA: 97 MOZ Rank: 48

  • Inhibitors of Cyclin-Dependent Kinases: Types and Their …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001317/

    WEBMar 10, 2021 · Recent studies on cyclin-dependent kinase (CDK) inhibitors have revealed that small molecule drugs have become very attractive for the treatment of cancer and neurodegenerative disorders. Most CDK inhibitors have been developed to …

    DA: 96 PA: 77 MOZ Rank: 29

  • The CDK4/6 inhibitor revolution - Nature

    nature.com

    https://www.nature.com/articles/s41571-023-00840-4

    WEBDec 11, 2023 · Cyclin-dependent kinase (CDK) 4/6 inhibitors inhibit the cell cycle, thus inducing cellular senescence and are increasingly being implicated in antitumour immunity.

    DA: 83 PA: 42 MOZ Rank: 61

  • Inhibition of the CDK2 and Cyclin A complex leads to ... - Nature

    nature.com

    https://www.nature.com/articles/s41467-022-30264-0

    WEBMay 20, 2022 · 25 Citations. 8 Altmetric. Metrics. Abstract. Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy,...

    DA: 14 PA: 27 MOZ Rank: 31

  • CDK inhibitors from past to present: A new wave of cancer therapy

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S1044579X22002607

    WEBJan 1, 2023 · Trilaciclib is the newest 3rd generation CDK 4/6 inhibitor that has recently been approved in the United States for the treatment of small cell lung cancer patients to reduce the bone marrow suppression brought on by chemotherapy.

    DA: 13 PA: 66 MOZ Rank: 54

  • CDK7 inhibitors as anticancer drugs - PMC - National Center for

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497306/

    WEBMay 8, 2020 · Preclinical studies have shown that CDK7i cause cell cycle arrest, apoptosis and repression of transcription, particularly of super-enhancer-associated genes in cancer, and have demonstrated their potential for overcoming resistance to cancer treatments.

    DA: 66 PA: 19 MOZ Rank: 83